Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04020185
Title Safety and Efficacy Study of IMSA101 in Refractory Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors ImmuneSensor Therapeutics Inc.
Indications

melanoma

lung non-small cell carcinoma

gastroesophageal cancer

hematologic cancer

renal cell carcinoma

progesterone-receptor negative breast cancer

hepatocellular carcinoma

estrogen-receptor negative breast cancer

head and neck cancer

Advanced Solid Tumor

Therapies

IMSA101 + unspecified PD-L1 antibody

IMSA101 + unspecified PD-1 antibody

IMSA101

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.